Please enable Javascript
Hans Hammers, MD, PhD
Hans Hammers, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center
Articles by Hans Hammers, MD, PhD
Front-Line Therapy in Papillary Renal Cancer: Live Session From The Uromigos Live & Unplugged 2024
Brian Rini, MD, FASCO
Renal Cell Carcinoma
|
October 2, 2024
Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024.
View More
The Uromigos' Definition of Oligometastatic: Live Session From The Uromigos Live & Unplugged 2024
Thomas Powles, MBBS, MRCP, MD
Renal Cell Carcinoma
|
October 2, 2024
View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024.
View More
Looking Ahead in RCC: Belzutifan, Triplets, Treatment Combinations, and More
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
View More
CheckMate 67T and the Potential of Subcutaneous Nivolumab Administration
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
View More
CheckMate 9ER: What Is the Impact for RCC?
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
View More
Panel Shares Thoughts on RCC Data: CheckMate 914, 214 and IMDC Selection Criteria
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
View More
Panel Discussion on OS Data From KEYNOTE-564 Study and Post-Relapse Treatment Selection
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
View More
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
View More
Frontline RCC Treatment Selection: IO/IO Versus IO/TKI
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
View More
RCC Panel Shares What They Are Most Excited About in the Field
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
View More
Phase 2 TIDE-A Study: Thoughts and Potential Treatment Impacts
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
View More
RCC Panel Reacts to LITESPARK-005 Data Presented at ESMO 2023
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
View More
Focus on Non-Clear Cell RCC: Frontline Treatment Options, Research Limitations, and More
Brian Rini, MD, FASCO
Roundtable
|
December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
View More
Panel Discusses the Value of Immunotherapy in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
View More
ESMO 2023: RENOTORCH Assesses Toripalimab and Axitinib in RCC
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
View More
Frontline Clear Cell Kidney Cancer: Treatment Selection and Patient Considerations
Brian Rini, MD, FASCO
Roundtable
|
November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
View More
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Hans Hammers, MD, PhD
Renal Cell Carcinoma
|
September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Read More